Table 5.

Autoantibodies against ECH1 and HNRNPA2B1 on effect of patients and disease characteristics in validation set 2.

		Anti-ECH1 (cutoff: 0.163)				Anti-HNRNPA2B1 (cutoff: 0.202)
	n	Median, IQR	p	Frequency (%)	p	Median, IQR	p	Frequency (%)	p
Gender			0.275a		0.921b		0.631a		0.406b
Male	35	0.200, 0.144		22 (62.9)		0.251, 0.103		27 (77.1)
Female	55	0.180, 0.126		33 (60.7)		0.245, 0.129		38 (69.1)
Age			0.341a		0.586b		0.891a		0.537b
<65 y	35	0.174, 0.072		23 (65.7)		0.239, 0.078		24 (68.6)
≥ 65 y	55	0.204, 0.139		33 (60.0)		0.248, 0.083		41 (74.5)
Smoke			<0.001a		<0.001b		0.107a		0.070b
No	15	0.091, 0.075		3 (20.0)		0.201, 0.142		8 (53.3)
Yes	69	0.197, 0.064		53 (76.8)		0.243, 0.076		55 (79.7)
<20 pack years	12	0.217, 0.070	0.811c	10 (83.3)	0.583b	0.266, 0.121	0.924c	10 (83.3)	0.921b
20–40 pack years	30	0.200, 0.062		24 (80.0)		0.255, 0.080		24 (80.0)
>40 pack years	27	0.200, 0.105		19 (70.4)		0.244, 0.076		21 (77.8)
Stage			0.411c		0.407b		0.012c		0.015b
I	30	0.207, 0.115		21 (70.0)		0.269, 0.064		27 (90.0)
II	30	0.175, 0.146		16 (53.3)		0.224, 0.142		17 (56.7)
III	30	0.183, 0.119		19 (63.3)		0.235, 0.099		21 (70.0)
Histological type
NSCLC			0.750a		1.000b		0.893a		1.000b
Adenocarcinoma	81	0.184, 0.136		50 (61.7)		0.246, 0.100		58 (71.6)
Squamous	6	0.207, 0.132		4 (66.7)		0.250, 0.176		4 (66.7)
LM			0.134a		0.293b		0.013a		0.006b
No	32	0.203, 0.133		22 (68.8)		0.261, 0.076		28 (87.5)
Yes	49	0.185, 0.139		28 (57.1)		0.213, 0.135		29 (59.2)

LM: lymph node metastasis; NSCLC: non-small cell lung cancer; IQR: inter-quartile range;

^aMann–Whitney test;

^bχ2 test;

^cKruscal–Wallis test